Additionally, METTL3 deficiency suppressed tumor growth in vivo, while MCAM overexpression abated the effect.<h4>Conclusion</h4>YY1/METTL3/IGF2BP1/MCAM axis aggravated OS development, which might provide novel therapy targets for OS. Here, IGF2BP1 is linked to neoplasm.